This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
by Zacks Equity Research
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
NVSNegative Net Change INCYPositive Net Change KPTIPositive Net Change
biotechnology biotechs medical pharmaceuticals
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
by Zacks Equity Research
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
INONegative Net Change ADMANegative Net Change RZLTNegative Net Change
biotechnology biotechs medical pharmaceuticals
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
by Zacks Equity Research
ImmunityBio stock sinks 21% after the FDA flags misleading claims on cancer drug Anktiva, citing exaggerated benefits and inadequate risk disclosures.
ANIPNegative Net Change IBRXNegative Net Change
biotechs medical
Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal
by Zacks Equity Research
GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.
GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
by Zacks Equity Research
IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.
ANIPNegative Net Change REPLNegative Net Change PHATNegative Net Change IBRXNegative Net Change
biotechs
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
by Zacks Equity Research
Valneva plunges 37% as Lyme vaccine study shows 70%+ efficacy but misses key statistical target, raising concerns despite plans for regulatory filings.
PFENegative Net Change ANIPNegative Net Change VALNNo Net Change
biotechs medical pharmaceuticals vaccines
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
by Zacks Equity Research
IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
ANIPNegative Net Change IONSPositive Net Change INDVPositive Net Change
biotechs
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
by Zacks Equity Research
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
NVOPositive Net Change LXRXNegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
by Zacks Equity Research
Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.
INONegative Net Change ADMANegative Net Change APGEPositive Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study
by Zacks Equity Research
Insmed stock jumps as Arikayce meets key goals in a late-stage study, paving the way for label expansion and a major boost to its potential market.
INSMNegative Net Change ANIPNegative Net Change
biotechs medical